However, no significant differences have been observed in SDC2 expression level, long-term prognosis, or major clinicopathological parameters compared GC patients with wild type (SDC2-WT) to those with SDC2 mutation (SDC2-MT) (Fig. S1A and S1B; Table S3), suggesting that SDC2 mutation was likely to be a passenger event 39. The gene discussed is SDC2; the disease is gastric cancer.